Getting serious about biosimilars
As patents on the first generation of monoclonal antibodies begin to expire, the cancer community will need to get to grips with the unique issues involved in ensuring the safety and efficacy of copies of [more]
regulation
Dangerous Healers
Its not uncommon for people diagnosed with cancer to explore how alternative practitioners might help. Some can, or at least do no harm. But the chances of running into a charlatan whose advice could be [more]
Walking the line between quick access and evidence
How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer [more]
Generic cancer drugs that we can trust
Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. Its good news for greater access, but patients want reassurance that switching to generics wont put them [more]
If you want better drugs consult a PRO
Our systems for evaluating new therapies are only as good as the accuracy of the judgements we make about how far patients benefit and how far they feel the burden of side-effects and other drawbacks. [more]
A seat at the table: patient advocates prepare for life on the inside
Little by little, patient advocates are winning their battle to be involved in decisions that affect them. They are now focusing on how to use their new-found voice to deliver real change for the people [more]
The patient touts
Christiane Hawranek and Marco Maurer, freelance print and radio journalists, won a Best Cancer Reporter Award for their exposé of the agencies that exploit foreign patients seeking treatment for cancer and other serious conditions. They [more]